

Special Issue

Radiochemotherapy, Radioimmunotherapy and Targeted Therapy in Locally Advanced and Metastatic Head and Neck Cancer

Message from the Guest Editor

Locally advanced head and neck cancer presents complex challenges for cancer management and significantly affects the overall survival rates of patients. Radiochemotherapy is the standard treatment modality for this type of cancer, either as a post-surgery adjuvant therapy or definitive therapy for non-operable tumors. In this Special Issue, we will examine the latest advancements in clinical research, cancer biology and precision medicine, all with the goal of achieving improved tumor eradication and minimizing toxicities associated with radiochemotherapy. We will also review the progress of targeted therapy and emerging immunotherapy with checkpoint inhibitors, particularly when used in combination with radiotherapy.

Guest Editor

Dr. Lianghao Ding

Department of Radiation Oncology, UT Southwestern Medical Center,
Dallas, TX, USA

Deadline for manuscript submissions

closed (20 September 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/177878

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)